Phaseline

Targets › TTR

TTR (Transthyretin): drug programs, companies and trials

10 programs from 8 companies in 17 trials: 10 Phase 3, 3 Phase 2, 3 Phase 4, 1 Phase 1; Cardiovascular, Neurology; next expected readout Jan 2027.

Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain. (UniProt, P02766)

Open in Phaseline: the race on TTR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Qilu PharmaceuticalTafamidis
Transthyretin stabiliser
TTRPhase 4Transthyretin Amyloid Polyneuropathy; Transthyretin Cardiac AmyloidosisJan 2028
Eidos Therapeutics, a BridgeBio companyAcoramidis
Transthyretin stabiliser
TTRPhase 4Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloid Cardiomyopathy, Transthyretin-Related; Amyloidosis; Amyloid CardiomyopathyApr 2028
AstraZenecaEplontersen
Transthyretin mRNA antisense inhibitor
TTRPhase 3Transthyretin Amyloid Cardiomyopathy; Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Jan 2027
Alnylam PharmaceuticalsVutrisiran
Transthyretin mRNA rnai inhibitor
TTRPhase 3Transthyretin Amyloidosis (ATTR) With CardiomyopathyJan 2027
Intellia Therapeuticsnexiguran ziclumeran (NTLA-2001)
in vivo CRISPR/Cas9 gene editing targeting TTR gene
TTRPhase 3Neuromuscular Disease; Transthyretin Amyloidosis (ATTR) With CardiomyopathyJul 2027
AstraZenecaALXN2220
anti-TTR monoclonal antibody
TTRPhase 3Transthyretin Amyloid CardiomyopathyDec 2027
Alnylam PharmaceuticalsNucresiran (ALN-TTRSC04)
TTR synthesis inhibitor; siRNA targeting TTR mRNA
TTRPhase 3Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; Transthyretin Amyloidosis With CardiomyopathyDec 2027
Ionis PharmaceuticalsEplontersen
Transthyretin mRNA antisense inhibitor
TTRPhase 3Hereditary Transthyretin-Mediated Amyloid PolyneuropathyAug 2029
NeurimmuneALXN2220
anti-transthyretin (TTR) monoclonal antibody
TTRPhase 2Amyloid Transthyretin Cardiomyopathy–
Novo NordiskCoramitug
Anti-transthyretin (TTR) monoclonal antibody; promotes removal of TTR amyloid deposits and
TTRPhase 1Transthyretin Amyloid CardiomyopathyMay 2027

Conditions

Transthyretin Amyloid Cardiomyopathy (3) Transthyretin Amyloidosis (ATTR) With Cardiomyopathy (2) Amyloid Transthyretin Cardiomyopathy (1) Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (1) Transthyretin Amyloidosis With Cardiomyopathy (1) Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (1) Neuromuscular Disease (1) Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) (1) Amyloid Cardiomyopathy, Transthyretin-Related (1) Amyloidosis (1) Amyloid Cardiomyopathy (1) Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (1)

Modalities

small molecule (4), other (4), antibody (1), protein or peptide (1)

Companies

Alnylam Pharmaceuticals (2) AstraZeneca (2) Novo Nordisk (1) Neurimmune (1) Intellia Therapeutics (1) Eidos Therapeutics, a BridgeBio company (1) Ionis Pharmaceuticals (1) Qilu Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.